MedTrace Logo

Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

NCT05194371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2022-01-18

No results posted yet for this study

Summary

In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.

Conditions

  • Esophageal Neoplasms

Interventions

RADIATION

definitive radiotherapy or definitive chemoradiotherapy

A total dose of radiation therapy should be more than 50Gy

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Lvhua Wang · National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medic

  • Kuaile Zhao · Fudan University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-10-31
Completion
2021-12-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05194371 on ClinicalTrials.gov